{"SPADE_N_06298": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_N_06298", "Peptide Name": "LfcinB", "Source": "Bovine lactoferrin (Lf-B)", "Family": "", "Gene": "Not found", "Sequence": "FKCRRWQWRMKK", "Sequence Length": 12, "UniProt Entry": ["http://www.uniprot.org/uniprot/P24627"], "Protein Existence": "Not found", "Biological Activity": ["Antimicrobial", "Anticancer"], "Target Organism": "Tumor cells:Ramos (IC50=10 µM); Raji (IC50=13 µM); Kelly (IC50=141 ± 3 µM); HT-29 (IC50=148±8 µM); SU-DHL-4 (IC50=16 µM); KMS-5 (IC50=38 µM); FEMX-I (IC50=40±7 µM); U266B1 (IC50=55 µM); KMM-1 (IC50=57 µM); MT-1 (IC50>160 µM)", "Hemolytic Activity": "Not available", "Cytotoxicity": "Not available", "Binding Target": "Not available", "Linear/Cyclic": "Linear", "N-terminal Modification": "Free", "C-terminal Modification": "Free", "Stereochemistry": "L", "Structure Description": "Not found", "Formula": "C80H125N27O14S2", "Mass": 1753.15, "PI": 11.74, "Net Charge": 6, "Hydrophobicity": -1.94, "Half Life": "Mammalian:1.1 hourYeast:3 minE.coli:2 min", "Comments": "Peptides induce lysis of cancer cells through interactions with the plasma membrane", "Literature": [{"Title": "The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells", "Pubmed ID": "19527490", "Reference": "BMC Cancer. 2009 Jun 15;9183.", "Author": "Fadnes B, Rekdal O, Uhlin-Hansen L.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=19527490"}], "Frequent Amino Acids": "KRW", "Absent Amino Acids": "ADEGHILNOPSTUVY", "Basic Residues": 6, "Acidic Residues": 0, "Hydrophobic Residues": 4, "Polar Residues": 8, "Positive Residues": 6, "Negative Residues": 0, "Similar Sequences": [{"SPADE_ID": "SPADE_N_02451", "Similarity": 1.0, "Sequence": "FKCRRWQWRMKKLGAPSITCVRRAF"}, {"SPADE_ID": "SPADE_N_06289", "Similarity": 1.0, "Sequence": "FKCRRWQWRMKKLGAPSITCVR"}, {"SPADE_ID": "SPADE_N_07664", "Similarity": 1.0, "Sequence": "FKCRRWQWRM"}]}}}